These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

506 related articles for article (PubMed ID: 32393915)

  • 1. Biggest COVID-19 trial tests repurposed drugs first.
    Nat Biotechnol; 2020 May; 38(5):510. PubMed ID: 32393915
    [No Abstract]   [Full Text] [Related]  

  • 2. Rigorous Randomized Controlled Trial Implementation in the Era of COVID-19.
    Oldenburg CE; Doan T
    Am J Trop Med Hyg; 2020 Jun; 102(6):1154-1155. PubMed ID: 32297590
    [No Abstract]   [Full Text] [Related]  

  • 3. Some drugs for COVID-19.
    Med Lett Drugs Ther; 2020 Apr; 62(1595):49-50. PubMed ID: 32324177
    [No Abstract]   [Full Text] [Related]  

  • 4. The Good, the Bad, and the Hoax: When Publication Instantaneously Impacts Treatment Strategies for COVID-19.
    Danion F; Ruch Y; Fourtage M; Kaeuffer C; Greigert V; Lefebvre N; Muller J; Nai T; Hansmann Y
    Antimicrob Agents Chemother; 2020 Jul; 64(8):. PubMed ID: 32513798
    [No Abstract]   [Full Text] [Related]  

  • 5. Clinical Trials of Repurposed Antivirals for SARS-CoV-2.
    Martinez MA
    Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32631826
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of Interferon Beta 1a, compared to Interferon Beta 1b and the usual therapeutic regimen to treat adults with moderate to severe COVID-19: structured summary of a study protocol for a randomized controlled trial.
    Irvani SSN; Golmohammadi M; Pourhoseingholi MA; Shokouhi S; Darazam IA
    Trials; 2020 Jun; 21(1):473. PubMed ID: 32493468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protocol for the DisCoVeRy trial: multicentre, adaptive, randomised trial of the safety and efficacy of treatments for COVID-19 in hospitalised adults.
    Ader F;
    BMJ Open; 2020 Sep; 10(9):e041437. PubMed ID: 32958495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Race to find COVID-19 treatments accelerates.
    Kupferschmidt K; Cohen J
    Science; 2020 Mar; 367(6485):1412-1413. PubMed ID: 32217705
    [No Abstract]   [Full Text] [Related]  

  • 9. Safety and effectiveness of azithromycin in patients with COVID-19: An open-label randomised trial.
    Sekhavati E; Jafari F; SeyedAlinaghi S; Jamalimoghadamsiahkali S; Sadr S; Tabarestani M; Pirhayati M; Zendehdel A; Manafi N; Hajiabdolbaghi M; Ahmadinejad Z; Kouchak HE; Jafari S; Khalili H; Salehi M; Seifi A; Golestan FS; Ghiasvand F
    Int J Antimicrob Agents; 2020 Oct; 56(4):106143. PubMed ID: 32853672
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of antiviral combination therapy in symptomatic patients of Covid-19 infection - a randomised controlled trial (SEV-COVID Trial): A structured summary of a study protocol for a randomized controlled trial.
    Panda PK; Bandyopadhyay A; Singh BC; Moirangthem B; Chikara G; Saha S; Bahurupi YA
    Trials; 2020 Oct; 21(1):866. PubMed ID: 33081849
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of hydroxychloroquine, lopinavir/ritonavir, and standard of care in critically ill patients with SARS-CoV-2 pneumonia: an opportunistic retrospective analysis.
    Lecronier M; Beurton A; Burrel S; Haudebourg L; Deleris R; Le Marec J; Virolle S; Nemlaghi S; Bureau C; Mora P; De Sarcus M; Clovet O; Duceau B; Grisot PH; Pari MH; Arzoine J; Clarac U; Boutolleau D; Raux M; Delemazure J; Faure M; Decavele M; Morawiec E; Mayaux J; Demoule A; Dres M
    Crit Care; 2020 Jul; 24(1):418. PubMed ID: 32653015
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Baricitinib as rescue therapy in a patient with COVID-19 with no complete response to sarilumab.
    Cingolani A; Tummolo AM; Montemurro G; Gremese E; Larosa L; Cipriani MC; Pasciuto G; Liperoti R; Murri R; Pirronti T; Cauda R; Fantoni M;
    Infection; 2020 Oct; 48(5):767-771. PubMed ID: 32642806
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lopinavir/ritonavir combination therapy amongst symptomatic coronavirus disease 2019 patients in India: Protocol for restricted public health emergency use.
    Bhatnagar T; Murhekar MV; Soneja M; Gupta N; Giri S; Wig N; Gangakhedkar R
    Indian J Med Res; 2020 Feb & Mar; 151(2 & 3):184-189. PubMed ID: 32362644
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Active tuberculosis, sequelae and COVID-19 co-infection: first cohort of 49 cases.
    Tadolini M; Codecasa LR; García-García JM; Blanc FX; Borisov S; Alffenaar JW; Andréjak C; Bachez P; Bart PA; Belilovski E; Cardoso-Landivar J; Centis R; D'Ambrosio L; Luiza De Souza-Galvão M; Dominguez-Castellano A; Dourmane S; Fréchet Jachym M; Froissart A; Giacomet V; Goletti D; Grard S; Gualano G; Izadifar A; Le Du D; Marín Royo M; Mazza-Stalder J; Motta I; Ong CWM; Palmieri F; Rivière F; Rodrigo T; Silva DR; Sánchez-Montalvá A; Saporiti M; Scarpellini P; Schlemmer F; Spanevello A; Sumarokova E; Tabernero E; Tambyah PA; Tiberi S; Torre A; Visca D; Zabaleta Murguiondo M; Sotgiu G; Migliori GB
    Eur Respir J; 2020 Jul; 56(1):. PubMed ID: 32457198
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Retrospective Controlled Cohort Study of the Impact of Glucocorticoid Treatment in SARS-CoV-2 Infection Mortality.
    Fernández-Cruz A; Ruiz-Antorán B; Muñoz-Gómez A; Sancho-López A; Mills-Sánchez P; Centeno-Soto GA; Blanco-Alonso S; Javaloyes-Garachana L; Galán-Gómez A; Valencia-Alijo Á; Gómez-Irusta J; Payares-Herrera C; Morrás-Torre I; Sánchez-Chica E; Delgado-Téllez-de-Cepeda L; Callejas-Díaz A; Ramos-Martínez A; Múñez-Rubio E; Avendaño-Solá C
    Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32571831
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lopinavir/ritonavir use in Covid-19 infection: is it completely non-beneficial?
    Owa AB; Owa OT
    J Microbiol Immunol Infect; 2020 Oct; 53(5):674-675. PubMed ID: 32474026
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of Hydroxychloroquine and Chloroquine During the COVID-19 Pandemic: What Every Clinician Should Know.
    Yazdany J; Kim AHJ
    Ann Intern Med; 2020 Jun; 172(11):754-755. PubMed ID: 32232419
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular Safety of Potential Drugs for the Treatment of Coronavirus Disease 2019.
    Aggarwal G; Henry BM; Aggarwal S; Bangalore S
    Am J Cardiol; 2020 Aug; 128():147-150. PubMed ID: 32425199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. COVID-19 research: an opinion piece.
    Waters L; Rockstroh JK
    HIV Med; 2020 Sep; 21(8):536-540. PubMed ID: 32544304
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of medical care, including use of anti-infective agents, on prognosis of COVID-19 hospitalized patients over time.
    Davido B; Boussaid G; Vaugier I; Lansaman T; Bouchand F; Lawrence C; Alvarez JC; Moine P; Perronne V; Barbot F; Saleh-Mghir A; Perronne C; Annane D; De Truchis P;
    Int J Antimicrob Agents; 2020 Oct; 56(4):106129. PubMed ID: 32755653
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.